Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases. These include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's, Parkinson's, and Huntington's disease, which are all characterized by cellular disequilibrium caused by the production and decreased clearance of neurotoxic proteins. The company’s therapeutic platform is uniquely positioned to discover and develop small molecule drugs with distinct molecular approaches that can 1) increase autophagy to more rapidly clear toxic proteins and 2) attenuate the production of neurotoxic proteins.